These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. Bartosch B; Verney G; Dreux M; Donot P; Morice Y; Penin F; Pawlotsky JM; Lavillette D; Cosset FL J Virol; 2005 Jul; 79(13):8217-29. PubMed ID: 15956567 [TBL] [Abstract][Full Text] [Related]
23. A laboratory-adapted HCV JFH-1 strain is sensitive to neutralization and can gradually escape under the selection pressure of neutralizing human plasma. Song H; Ren F; Li J; Shi S; Yan L; Gao F; Li K; Zhuang H Virus Res; 2012 Oct; 169(1):154-61. PubMed ID: 22846920 [TBL] [Abstract][Full Text] [Related]
26. Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus. Lavillette D; Pécheur EI; Donot P; Fresquet J; Molle J; Corbau R; Dreux M; Penin F; Cosset FL J Virol; 2007 Aug; 81(16):8752-65. PubMed ID: 17537855 [TBL] [Abstract][Full Text] [Related]
27. Induction of broadly neutralising HCV antibodies in mice by integration-deficient lentiviral vector-based pseudotyped particles. Deng Y; Guan J; Wen B; Zhu N; Chen H; Song J; Yang Y; Wang Y; Tan W PLoS One; 2013; 8(4):e62684. PubMed ID: 23626846 [TBL] [Abstract][Full Text] [Related]
28. An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development. Salas JH; Urbanowicz RA; Guest JD; Frumento N; Figueroa A; Clark KE; Keck Z; Cowton VM; Cole SJ; Patel AH; Fuerst TR; Drummer HE; Major M; Tarr AW; Ball JK; Law M; Pierce BG; Foung SKH; Bailey JR Gastroenterology; 2022 Feb; 162(2):562-574. PubMed ID: 34655573 [TBL] [Abstract][Full Text] [Related]
29. Screening of small-molecule compounds as inhibitors of HCV entry. Yang JP; Zhou D; Wong-Staal F Methods Mol Biol; 2009; 510():295-304. PubMed ID: 19009270 [TBL] [Abstract][Full Text] [Related]
30. Optimization of the pseudoparticle system for standardized assessments of neutralizing antibodies against hepatitis C virus. Chumbe A; Urbanowicz RA; Sliepen K; Koekkoek SM; Molenkamp R; Tarr AW; Ball JK; Schinkel J; van Gils MJ J Gen Virol; 2022 Nov; 103(11):. PubMed ID: 36399377 [TBL] [Abstract][Full Text] [Related]
32. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. Meunier JC; Russell RS; Goossens V; Priem S; Walter H; Depla E; Union A; Faulk KN; Bukh J; Emerson SU; Purcell RH J Virol; 2008 Jan; 82(2):966-73. PubMed ID: 17977972 [TBL] [Abstract][Full Text] [Related]
33. Morphological identification of hepatitis C virus E1 and E2 envelope glycoproteins on the virion surface using immunogold electron microscopy. Kaito M; Watanabe S; Tanaka H; Fujita N; Konishi M; Iwasa M; Kobayashi Y; Gabazza EC; Adachi Y; Tsukiyama-Kohara K; Kohara M Int J Mol Med; 2006 Oct; 18(4):673-8. PubMed ID: 16964422 [TBL] [Abstract][Full Text] [Related]
34. [Generation of six genotypes of infectious HCV pseudo-particles and detection of neutralizing antibodies in HCV patients]. Yang XF; Pan L; Wang Y; Ma L; Zhang Y; Zhou Y; Hao CQ; Ma ZY; Jia ZS Zhonghua Gan Zang Bing Za Zhi; 2013 Dec; 21(12):903-6. PubMed ID: 24636291 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of the binding of HCV serum particles to human hepatocytes by E1E2-specific D32.10 monoclonal antibody. Ndongo N; Rechoum Y; De Sequeira S; Zoulim F; Trépo C; Drouet E; Petit MA J Med Virol; 2009 Oct; 81(10):1726-33. PubMed ID: 19697405 [TBL] [Abstract][Full Text] [Related]
36. Characterization of Glycoproteins and Preparation of HCV Pseudoparticles with High Infectivity of Subtype 3b from Chinese Patients. Tao G; Ye F; Deng Y; Zhang L; Lu S; Bo X; Li C; Shen X; Tan W Bing Du Xue Bao; 2017 Jan; 33(1):56-60. PubMed ID: 30702822 [TBL] [Abstract][Full Text] [Related]
37. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice. Zeng R; Li G; Ling S; Zhang H; Yao Z; Xiu B; He F; Huang R; Wei L Antiviral Res; 2009 Oct; 84(1):23-30. PubMed ID: 19646486 [TBL] [Abstract][Full Text] [Related]
38. Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. Goffard A; Callens N; Bartosch B; Wychowski C; Cosset FL; Montpellier C; Dubuisson J J Virol; 2005 Jul; 79(13):8400-9. PubMed ID: 15956584 [TBL] [Abstract][Full Text] [Related]
39. HCV envelope protein function is dependent on the peptides preceding the glycoproteins. Bian T; Zhou Y; Bi S; Tan W; Wang Y Biochem Biophys Res Commun; 2009 Jan; 378(1):118-22. PubMed ID: 19013428 [TBL] [Abstract][Full Text] [Related]
40. High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry. Voisset C; de Beeck AO; Horellou P; Dreux M; Gustot T; Duverlie G; Cosset FL; Vu-Dac N; Dubuisson J J Gen Virol; 2006 Sep; 87(Pt 9):2577-2581. PubMed ID: 16894196 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]